A new attempt to simplify cell therapy
Researchers in China have reported an experimental cancer-treatment strategy that uses engineered red blood cells to deliver genetic instructions directly inside the body, with the goal of turning a patient’s own immune cells into tumor-fighting agents without the usual lab-based manufacturing step.
The work, published in Science Translational Medicine, centers on a platform the team calls mRNA-LNP-Ery. In the system, messenger RNA is packaged into lipid nanoparticles and then attached to erythrocytes, or red blood cells. Those red blood cells act as carriers, transporting the genetic cargo through the body so it can be taken up by myeloid immune cells.
That matters because current CAR therapies are typically built around a slow and expensive workflow. Clinicians collect a patient’s cells, genetically modify them outside the body, expand them, and infuse them back weeks later. The new approach aims to skip much of that process by performing the reprogramming in vivo rather than ex vivo.
How the platform works
According to the study summary, the researchers used red blood cells as delivery vehicles for mRNA encoding chimeric antigen receptor, or CAR, constructs. Once those instructions are delivered, myeloid cells begin expressing engineered receptors that help them recognize and attack cancer cells.
The target here is distinct from better-known CAR-T therapies. T cells belong to the adaptive immune system and have been the backbone of several approved engineered-cell treatments. Myeloid cells, which include macrophages, occupy a different niche. They are deeply involved in the tumor microenvironment, where cancers often suppress immune activity or co-opt surrounding cells to support growth.
By redirecting myeloid cells, the researchers are trying to intervene closer to the environment that helps solid tumors persist. That is one reason the study stands out. Many of the hardest problems in cancer immunotherapy involve getting engineered immune responses to work reliably against solid tumors rather than blood cancers.
Why red blood cells are useful carriers
Red blood cells circulate widely, are abundant, and do not have nuclei of their own, making them appealing as delivery platforms. In this study, they were used as temporary shuttles rather than therapeutic effectors. The lipid nanoparticles attached to them carry the mRNA payload, and the system is designed to improve where that payload goes once it enters circulation.
The paper summary says the platform mediates recognition and uptake in the spleen, helping deliver the nanoparticles to immune cells that can then be reprogrammed. That route could offer a way to shape immune behavior without extracting cells from the patient first.
The concept also fits a broader trend in biomedicine: using mRNA not only for vaccines, but as a flexible instruction set for transient therapeutic programming. Instead of permanently altering DNA, mRNA gives cells a temporary blueprint for making a protein of interest. In cancer, that can be a useful tradeoff if the goal is to trigger a targeted immune response while limiting long-term changes.
What the study suggests
The authors describe the work as a platform for engineering myeloid cells with CARs using erythrocyte-mediated mRNA delivery. In practical terms, the study suggests that the body itself could become the manufacturing site for at least some forms of cell therapy.
If that idea proves durable, it could address several bottlenecks that limit access to personalized immunotherapies today:
- Complex manufacturing timelines that can stretch for weeks
- High production costs tied to specialized facilities
- Logistical hurdles around collecting, modifying, and returning patient cells
- Difficulties extending cell-therapy success into solid tumors
Those are large ifs. The study is a research-stage result, not a clinical product, and the summary provided does not establish efficacy in human patients at scale or long-term safety. But it does outline a plausible route toward a more modular form of immune engineering.
The broader significance
One reason this work is likely to draw attention is that it shifts the question from how to manufacture ever more elaborate cell therapies to how to deliver instructions precisely enough that the body can do more of the work itself.
That is a meaningful conceptual change. Conventional CAR workflows treat the patient as the endpoint of a manufacturing chain. This platform instead treats the patient as the site where immune programming can happen. If researchers can control that process safely, the economics and speed of advanced cancer therapy could change substantially.
It also highlights growing interest in myeloid biology. Tumors are not just masses of malignant cells. They are ecosystems. Therapies that can alter the behavior of immune cells embedded in that ecosystem may have advantages where other approaches stall.
What comes next
The immediate next questions are predictable but important: how efficiently the delivery system works across tumor types, how durable the engineered response is, whether off-target immune effects can be controlled, and whether repeated dosing is feasible.
Researchers will also need to show that the platform can generate meaningful anti-tumor activity in settings that resemble real clinical use, not only carefully tuned experimental models. Delivery, targeting, dose control, and safety will determine whether this becomes a practical treatment strategy or remains an elegant laboratory demonstration.
Still, the result captures a direction of travel in oncology. The field is moving toward therapies that are less bespoke at the factory level and more programmable at the biological level. Using red blood cells to ferry mRNA instructions to immune cells is an early example of that shift, and one that could prove influential if follow-on studies support the promise.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
